

Laurence Buisseret

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4191833/publications.pdf>

Version: 2024-02-01

18
papers

3,057
citations

567281

15
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

6041
citing authors

#	ARTICLE	IF	CITATIONS
1	High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer. , 2021, 9, e001965.		16
2	Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach. Journal of the National Cancer Institute, 2020, 112, 708-719.	6.3	111
3	Management of early breast cancer in patients bearing germline BRCA mutations. Seminars in Oncology, 2020, 47, 243-248.	2.2	3
4	The adenosine pathway in immuno-oncology. Nature Reviews Clinical Oncology, 2020, 17, 611-629.	27.6	275
5	The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). Acta Oncol ³ gica, 2020, 59, 723-725.	1.8	7
6	Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasis. Oncolmmunology, 2019, 8, 1601481.	4.6	24
7	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. Breast Cancer Research, 2019, 21, 151.	5.0	30
8	Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer. JCI Insight, 2019, 4, .	5.0	182
9	Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. Journal of Clinical Investigation, 2019, 129, 1785-1800.	8.2	266
10	Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. Annals of Oncology, 2018, 29, 1056-1062.	1.2	138
11	Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer. Frontiers in Immunology, 2018, 9, 2660.	4.8	65
12	Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. Modern Pathology, 2017, 30, 1204-1212.	5.5	81
13	Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncolmmunology, 2017, 6, e1257452.	4.6	169
14	CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. Cancer Research, 2017, 77, 5652-5663.	0.9	90
15	Targeting immune checkpoints in breast cancer: an update of early results. ESMO Open, 2017, 2, e000255.	4.5	118
16	CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. JCI Insight, 2017, 2, .	5.0	258
17	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Journal of Clinical Oncology, 2016, 34, 2460-2467.	1.6	1,185
18	A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes. Journal of Visualized Experiments, 2014, , .	0.3	33